Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States
Authors:
Open Access
- 8 November 2024
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (12) , 2597-2615
Abstract
Introduction Given the recent approval and recommendation of V116, a 21-valent pneumococcal conjugate vaccine (PCV), in the United States (US), we evaluated the cost-effectiveness of using V116 versus the 20-valent PCV (PCV20) or the 15-valent PCV (PCV15) in series with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) among adults aged ≥ 65 years in the US who had never received a PCV previously. Methods A static multi-cohort state-transition Markov model was developed to estimate the lifetime incremental clinical and economic impact of V116 vs. PCV20 or PCV15 + PPSV23 from the societal perspective. All model inputs were based on published literature and publicly available databases and/or reports. Model outcomes included undiscounted clinical cases: invasive pneumococcal disease (IPD), inpatient and outpatient non-bacteremic pneumococcal pneumonia (NBPP), post-meningitis sequelae (PMS), deaths from IPD and inpatient NBPP, discounted quality-adjusted life years (QALYs) as well as the discounted total cost (in 2023 USD), which consisted of vaccine acquisition and administration costs, direct and indirect costs associated with the disease, and travel costs for vaccination. The final summary measure was the incremental cost-effectiveness ratio (ICER), reported as $/QALY gained. Three percent was used for the annual discounting rate. Results Based on the inputs and assumptions used, the results indicated that the V116 strategy prevented 27,766 and 32,387 disease cases/deaths and saved $239 million and $1.8 billion in total costs when compared to the PCV20 and PCV15 + PPSV23 strategies, respectively, in vaccine-naïve adults aged ≥ 65 years. The estimated ICERs were cost saving in both regimens (i.e., V116 vs. PCV20 or vs. PCV15 + PPSV23). The scenario analysis and deterministic and probabilistic sensitivity analyses also demonstrated the robustness of the qualitative results. Conclusions These results demonstrated that using V116 in adults aged ≥ 65 years in the US can prevent a substantial number of PD cases and deaths while remaining highly favorable economically over a wide range of inputs and scenarios.Keywords
Funding Information
- Merck & Co., Inc., Rahway, NJ, USA
This publication has 47 references indexed in Scilit:
- Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United StatesInfectious Diseases and Therapy, 2024
- Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and AssumptionsPharmacoEconomics, 2019
- Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and WaleseClinicalMedicine, 2018
- Verification of Decision-Analytic Models for Health Economic Evaluations: An OverviewPharmacoEconomics, 2017
- Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United StatesJournal of General Internal Medicine, 2016
- Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013Journal of Prevention, 2015
- Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United StatesVaccine, 2010
- Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: A systematic review of conclusions and assumptionsVaccine, 2009
- Influenza VaccinationAmerican Journal of Preventive Medicine, 2006
- Recommendations of the Panel on Cost-effectiveness in Health and Medicine1996